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CASE OF THE MONTH SUBMISSION
A 39-year-old woman nonsmoker presented in August 2007 
with chest wall discomfort. Computed tomography (CT) 
revealed right upper lobe parenchymal and pleural abnormali-
ties as well as mediastianal lymphadenopathy. Bronchoscopy 
and mediastinoscopy yielded a diagnosis of adenocarcinoma 
of the lung. No mutations in KRAS or epidermal growth factor 
receptor (EGFR) were identified.
She received four cycles of carboplatin, paclitaxel, and 
bevacizumab followed by maintenance bevacizumab and erlo-
tinib. Her tissue was reanalyzed and an anaplastic lymphoma 
kinase (ALK) rearrangement was detected. After disease pro-
gression in March 2011, she began crizotinib 250 mg orally 
twice daily on a phase II clinical trial (PROFILE 1005), ulti-
mately achieving a complete remission. Initial magnetic reso-
nance imaging (MRI) imaging of the brain was negative.
In July 2011, she developed pupil asymmetry. MRI of the 
brain revealed multiple, bilateral, cystic lesions without patho-
logical enhancement. Lumbar puncture was unremarkable. 
Crizotinib was continued. She received Cyberknife therapy to 
a lesion in the thalamus and the other lesions were observed.
In September 2013, MRI of the brain demonstrated pro-
gression in size and number of the parenchymal cystic brain 
lesions (Fig. 1A, B). A CT scan of the chest and abdomen done 
at that time demonstrated disease stability. She underwent 
image-guided frontal craniotomy with biopsy of two cystic 
lesions. Pathology confirmed metastatic lung adenocarci-
noma. The patient declined whole brain radiation therapy and 
began treatment with ceritinib (LDK387) in January 2014. An 
MRI of the brain performed in September 2014 demonstrated 
reduction of the previously noted brain metastases (Fig. 2). A 
chest-CT scan demonstrated continued stability of her sys-
temic disease at that time.
DISCUSSION
The ALK rearrangement defines a distinct molecular 
subgroup within non–small-cell lung cancer. Its discovery 
has spurred the development of multiple molecular targeted 
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FIGURE 1. A, B, MRI showing multi-
ple varying-sized cystic lesions within 
the brain parenchyma (A) axial T1 
flair, (B) axial T2-postcontrast. MRI, 
magnetic resonance imaging.
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agents, including crizotinib and ceritinib. Despite the thera-
peutic efficacy of crizotinib,1 patients will ultimately develop 
resistance to therapy, usually in the central nervous system.2–6 
In addition, the cystic appearance of the brain metastases in 
our patient, as well as in two other case reports,3 describes a 
unique radiographic pattern in patients with ALK positivity.
This is the first case report with pathologic assessment 
of cystic central nervous system (CNS) lesions in patients tak-
ing crizotinib. Contrary to the first case report, which proposed 
a potential link between signet ring histology and cystic brain 
lesions,3 there were no signet ring cells in the CNS specimen in 
our case. This is also the first case report to explore the mecha-
nism of resistance in CNS lesions resistant to crizotinib. Targeted 
next-generation sequencing, utilizing the T5a test sequencing 287 
genes was performed (Foundation One, Foundation Medicine 
Inc., Cambridge, MA). No ALK resistance mutations were iden-
tified in the brain metastasis sample. No additional mutations 
imparting resistance were identified,7,8 raising the possibility of 
low CNS levels of crizotinib imparting resistance to the drug.9
The next-generation ALK inhibitor ceritinib recently 
received accelerated approval for the treatment of ALK-
positive patients resistant to and/or intolerant to crizotinib. 
In the phase I study of ceritinib, responses were observed in 
patients with brain metastases.10 Of note, the median progres-
sion-free survival after treatment with ceritinib was similar 
among patients with and without CNS metastases. Thus, the 
stability of the CNS lesions on ceritinib in our patient may 
reflect better CNS penetration.
Recently, several other next-generation ALK inhibi-
tors with promising CNS activity have been developed. In a 
phase I/II study of the novel ALK inhibitor alectinib, objective 
responses in the CNS were observed in 11 of 21 (52%) patients 
with brain metastases. Cerebrospinal fluid sampling in five 
patients documented alectinib penetration into the cerebrospi-
nal fluid compartment.11 Early studies of the next-generation 
ALK inhibitor AP26113 have also shown tumor regressions 
in 9 of 13 (69%) patients with untreated or progressing brain 
metastases.12 Moving forward, additional prospective data is 
needed to inform the duration of CNS responses in patients 
treated with second-generation ALK inhibitors and provide a 
better sense of the denominators of patients with CNS lesions 
treated with these agents.
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FIGURE 2.  MRI of the brain showing cystic brain metasta-
ses throughout the brain parenchyma that appears grossly 
unchanged or slightly decreased in size after 7 months of 
treatment with ceritinib (axial T2-postcontrast). MRI, mag-
netic resonance imaging.
